1. Anderson WF. Prospects for human gene therapy. Science 1984; 226:401-409.

2. Blaese RM, Anderson WF, Rosenberg SA, Culver KW. The ADA human gene therapy clinical protocol. Hum. Gene Ther 1990; 327-362.

3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos J. Genetic alterations during colorectal-tumor development. N. Engl. J. Med 1988; Sep 1; 319(9):525-532.

4. Freeman SM, Koeplin DS, Abboud CN, et al. The bystander effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274-5284.

5. Mullen CA. Metabolic suicide genes in gene therapy. Pharm. Ther 1994; Aug; 63(2):199-207.

6. Mullen CA. Metabolic suicide genes in gene therapy. Pharm. Ther 1994; 63:199-207.

7. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995; 2:702-709.

8. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst 1990; 82:297-300.

9. Abe A, Takeo T, Emi N, Tanimoto M, Ueda R, Yee JK, Friedman T, Saito H. Transduction of a drug sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. Proc. Soc. Exp. Biol. Med 1993; 203:354-359.

10. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986; 46:5276-5281.

11. Moolten FL. Drug sensitivity (''suicide'') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 4:279-287.

12. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis 1988; 10:s490-494.

13. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxmethly) guanine. Proc. Natl. Acad. Sci. USA 1997; 74:5716-5720.

14. Elion GB. The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzyme Regul 1980; 18:53-60.

15. Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob. Agents. Chemother 1987; 31:844-889.

16. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.

17. Olfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther 1993; 4:39-69.

18. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro sensitization system. Cancer Res 1994; 54:2055-2059.

19. O'Malley BWJ, Chen S, Schwartz MR, Woo SLC. Adenorivus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 55:1080-1085.

20. Freeman SM, McCune C, Robinson W, et al. Treatment of ovarian cancer using a gene-modified vaccine. Hum. Gene Ther 1995; 6:927-939.

21. Freeman SM, Abboud CN, Whartenby KA, Koeplin DS, Mool-ten FL, Abraham GN. The ''bystander effect'': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1999; 53:5274-5283.

22. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther 1993; 4:725-731.

23. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of HSVtk gene involves an immune component. Cancer Res 1994; 54:6223-6224.

24. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: Cloning sequencing and expression of E. coli cytosine deaminase. Mol. Pharmacol 1992; 43:380-387.

25. Mullen CA, Kilstrup M, Blaese M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc. Natl. Acad. Sci. USA 1992; 89:33-37.

26. Huber BE, Austin EA, Good SS, Knick VC, Tibbels T, Richards CA. In vivo anti-tumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cyto-sine deaminase. Cancer Res 1993; 53:4619-4626.

27. Nishiyama T, Kawamura Y, Kawamoto K, et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res 1985; 45:1753-1761.

28. Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol 1988; 6:1653-1644.

29. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 1991; 88:8039-8043.

30. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 1993; 12:195-212.

31. Clark AJ, et al. Selective cell ablation in transgenic mice expressing E. coli nitroreductase. Gene Ther 1997; 4:101-110.

32. Drabek D, Guy J, Craig R, Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther 1997; 4:93-100.

33. Bridgewater JA, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370.

34. Clarke L, Waxman DJ. Oxidation metabolism of cyclophospha-mide: Identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989; 49:2344-2350.

35. Wei MX, Tamiya T, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P4502B1 gene. Hum Gene Ther 1994; 5:969-978.

36. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1:1171-1177.

37. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GMF, Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by cartoxypeptidase G2. J Med Chem 1990; 33:677-681.

38. Niculescu-Duvaz I, Springer CJ. Gene-directed enzyme prodrug therapy (GDEPT): Choice of prodrugs. In: K.D. Bagshawe (ed.) Gene-Directed Enzyme Prodrug Therapy (GDEPT): Choice of Prodrugs. Amsterdam: Elsevier Science B.V 1996.

39. Marias R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustardd prodrug/car-

boxypeptidase G2 combination. Cancer Res 1996; 56: 4735-4742.

39a. Mroz PJ, Moolten FL. Retrovirally transfected Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum. Gene Ther 1993; 4: 589-595.

39b. Tamiya T, Ono Y, Wei MX, et al. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thiozanthine or 6-thioguanine. Cancer Gene Ther 1996; 3:155-162.

39c. SorscherEJ, Peng S, BebokZ, et al. Tumor cell bystander killing in colonic carcinoma utilizing the. Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1:233-238.

39d. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8:1637-1644.

40. Subak-Sharpe JH, Burk RR, Pitts JD. Metagolic cooperation by cell to cell transfer between genetically different mammalian cells. Heredity 1966; 21:342-343.

41. Gilula NB, Reeves OR, Steinbach A. Metabolic coupling, ionic coupling, and cell contacts. Nature 1972; 235:262-265.

42. Simpson I, Rose B, Lowenstein WR. Size limit of molexules permeating junctional membrane channels. Science 1977; 195: 294-296.

43. Beyer EC. Int Rev Cytol 1993; 137C:1-37.

44. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93:1831-1835.

45. Mesnil M, Krutovskikh V, Piccoli C, Elfgang C, Traub O, Willecke K, Yamasaki H. Cancer Res 1995; 55:629-639.

46. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzman JL, Klatzmann D. Regression of established microscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 1993; 90:7024-7028.

47. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol 1995; 154:5302-5312.

48. Gagandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: Involvement of an immunological component in the bystander effect. Cancer Gene Ther 1996; 3:83-88.

49. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the ''bystander effect'': A cytokine cascade. Exp. Haematol 1996; 24:829-838.

50. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 1994; 91:4348-4352.

51. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytisine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994; 54:1503-1506.

52. Misawa T, Chiang M, Scotzco L, et al. Induction of systemic responses against hepatic metastases by HSV1-TK ganciclovir treatment in a rat model. Cancer Gene Ther 1995; 2:332-337.

53. O'Malley BW, Sewell DA, Li D, Kosai K, Chen S, Woo SLC, Duan L. The role of Interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 1997; 11:667-673.

54. Rosenberg SA, Lotze M, Maul LM. A progress report on the treatment of 157 patients with advanced cancer using lympho-kine-activated killer cells and interleukin-2 or high-dose in-terleukin-2 alone. New Engl. J. Med 1987; 316:889-897.

55. West WH, Touer KW, Yanelli JR. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med 1987; 316:898-905.

56. West WH, Touer KW, Yanelli JR, et al. Constant infusion in-terleukin-2 in adoptive cellular therapy of cancer. Proc. ASCI 1987; 6:929-933.

57. Chen S, Li Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SLC. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 1995; 92:2577-2581.

58. O'Malley BW, Cope KA, Chen S, Li D, Schwartz MR, Woo SLC. Combination gene therapy for oral cancer in a murine model. Cancer Res 1996; 56:1737-1741.

59. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, Woo SL. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56(16): 3758-3762.

60. Dranoff G, Jaffe EM, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hirofumi H, Pardoll DM, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 1993; 90:3539-3543.

60a. Day K, Li D, Duan L, O'Malley BW. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer. The Laryngoscope 2001; 111(16): 801-806.

60b. Wybranietz WA, Gro CD, Phelan A, O'Hare P, Speigel M, et al. Enhanced suicide gene effect by adenoviral transuction of VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001; 8:1654-1664.

60c. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16:440-443.

60d. Dilber MS, et al. Intercellular delivery of thymidine kinase protein drug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6:2-21.

60e. Moriuchi S, Wolfe D, Tamura M, et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002; 9:584-591.

60f. Freytag SO, Khil M, Stricker KH, Peabody J, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62:4968-4976.

60g. Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO. Pronounced anti-tumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997; 3: 2081-2088.

61. Chu G, et al. Nucleic Acids Res 1987; 15:1311-1326.

62. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl. Acad. Sci. USA 1990; 87:9568-9572.

63. olff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-1468.

64. Sikes ML, O'Malley BWJ, Finegold MJ, Ledley FD. In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum. Gene Ther 1994; 5(16):837-884.

65. Felgner PL, Gadek TR, Holm M, et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 1987; 84:7413-7417.

66. Sugaya S, Fujita K, Kikuchi A, Ueda H, Takakuwa K, Kodama S, Tanaka K. Inhibition of tumor growth by the direct intratu-moral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum. Gene Ther 1996; 7(2):223-230.

67. Miller AD. Retrovirus packaging cells. Hum. Gene Ther 1990; 61:5-14.

68. Ledley FD. Human gene therapy. In: Jacobson GK, Jolly SO, Eds. Biotechnology, A Comprehensive Treatise: Weinhaim, 1989:399-461.

69. Habib NA, Ding S, El-Masry R, Dalla Serra G, Mikhail NE, Issi G, et al. Contrasting effects of direct p53 DNA injection in primary and secondary liver tumours. Tumor Targeting 1995; 1:295-298.

70. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167:400-406.

71. Heinrish MC, Keeble WW, Grompe M, Bagby GC, Hoatlin ME. A gibbone ape leukemia virus (GALV) pseudotyped retro viral vector for gene therapy of Fanconi anemia complenenta-tion group C (FACC). Blood 1994; 84(359a).

72. O'Malley BW, Ledley FD. Somatic gene therapy: Methods for the present and future. Arch. Otolaryngol. Head Neck Surg 1993; 119:1100-1107.

73. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl. Cancer Inst 1997; 89(1): 21-39.

74. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995; 270:404-410.

75. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91:6196-6200.

76. Wang Q, Finer MH. Second generation adenovirus vectors. Nature 1996; 2(16):714-716.

77. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases response in mouse liver. Proc. Natl. Acad. Sci. USA 1994; 91:6196-6200.

78. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol 1989; 63:3822-3828.

79. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995; 69(16):1479.

80. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient de-lection mutant packaging system for defective herpes simplex virus vectors: potential application to human gene therapy and neuronal physiology. Proc. Natl. Acad. Sci. USA 1990; 87: 8950-8954.

81. McCormick F. Interactions between adenovirus proteins and the p53 pathway: The development of ONYX-015. Semin Cancer Biol 2000; 10(16):453-459.

82. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 73; 8(16).

83. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report, end 1996. Hum Gene Ther 1997; 8:775-880.

84. Rochlitz CF. Gene therapy of cancer. Swiss Med Wkly 2001; 131(1-2):4-9.

85. Hollon T. Gene therapy—A loss of innocence. Nature Med 2000; 6:1-2.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment